Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
Inventors
Santora, Vincent John • Chen, Mi • Chung, DeMichael
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Substituted benzoxazole and benzofuran chemical entities of Formula (I): wherein, V, W, X, Y, Z, and m have any of the values described herein and compositions comprising such chemical entities; processes for making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; and the treatment of one or more disorders, including neurological, cognitive, immunological, and inflammatory disorders, as well as other conditions and diseases involving PDE7 or cyclic nucleotide signaling.
Core Innovation
The invention relates to compounds of Formula (I), Formula (II), and Formula (III), including pharmaceutically acceptable salts, defined by spiro-fused quinazoline scaffolds such as spiro[cyclohexane-1,9′-furo[2,3-f]quinazoline] and spiro[[1,3]oxazolo[5,4-f]quinazoline-9,1′-cyclohexane] derivatives. The structural scope is governed by substituent variables X, Y, Z, V, W, and additional groups including L1-L5 and multiple R-group sets, with extensive optional substitution rules and ring-forming alternatives. The disclosure also includes specifically named spiro-fused quinazoline derivative embodiments and example compounds with structural depictions and analytical data.
Formula (II) and Formula (III) further define related structural variants by constraining Y, Z, V, and W to specified sets. In these formulas, V is selected from a bond and selected linker options, and W includes halo, alkyl, haloalkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, and N(Rb)2 options, with ring-forming alternatives where both Rb together form monocyclic, bicyclic, or tricyclic rings under defined constraints. The document presents the same spiro-fused quinazoline scaffold with different substituent selections and related sub-formulas.
The patent also presents PDE7 inhibitor chemical entities defined by Formula (I) and related sub-formulas, together with pharmaceutically acceptable salts. The compounds are positioned as inhibitors of PDE7 suitable for modulating aberrant or dysregulated PDE7-mediated signaling pathways. The partial content further describes characterization data for multiple specific compounds, including structural information, 1H NMR, and [M+H] mass or ion values.
Claims Coverage
The consolidated claims coverage includes compound claims for Formula (I), Formula (II), and Formula (III), a selection claim to specifically named spiro-fused quinazoline derivatives, and a method claim directed to treating disorders associated with an aberrant or dysregulated PDE7-mediated signaling pathway. Across these claims, the inventive features are the formula-defined spiro-fused quinazoline compounds, the constrained substituent options, the enumerated compound selection, and the therapeutic administration method.
Compound of Formula (I)
A compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein X is —CH or —N; Y is selected from —H, halo, and —C1-4 alkyl; each Z is independently selected from —H, halo, and —C1-4 alkyl; V is selected from a bond and multiple linkage options; each m and n is independently 0, 1, 2 or 3; L1-L5 and W are selected from recited structural sets; and R1A, R1B, R1C, R2A, R3A, R2AA, and R3AA are selected from defined substituent groups.
Compound of Formula (II)
A compound of Formula (II) or a pharmaceutically acceptable salt thereof, wherein Y is selected from —H, —F, —Cl, —Br, and —C1-4 alkyl; Z is selected from —H, —F, and —C1-4 alkyl; V is selected from a bond, —CH2—, —C(O)—, and —NRa— where Ra is defined; and W is selected from a defined group including halo, alkyl, haloalkyl, alkoxy, hydroxymethyl, hydroxyethyl, carbonyl-containing groups, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, and N(Rb)2 options, including ring-forming alternatives where both Rb together form a 4-15-membered monocyclic, bicyclic or tricyclic ring with defined heteroatom and substitution constraints.
Compound of Formula (III)
A compound of Formula (III) or a pharmaceutically acceptable salt thereof, wherein Y is selected from —H, —F, —Cl, —Br, and —C1-4 alkyl; Z is selected from —H, —F, and —CH3; V is selected from a bond, —CH2—, —C(O)—, and —NRa— where Ra is defined; and W is selected from a defined group including halo, alkyl, haloalkyl, alkoxy, hydroxymethyl, hydroxyethyl, carbonyl-containing groups, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, and N(Rb)2 options with defined ring-forming alternatives.
Enumerated spiro-fused quinazoline compounds
A compound selected from the group consisting of specific named spiro-fused quinazoline derivatives and pharmaceutically acceptable salts thereof, including carboxylate, carboxylic acid, carboxamide, ketone, and amino-methyl substituted embodiments.
PDE7-mediated disorder treatment administration
A method for treating, inhibiting, relieving, or ameliorating a disorder symptom in a subject with an aberrant or dysregulated PDE7-mediated signaling pathway by administering a compound of claim 1 or a pharmaceutically acceptable salt thereof.
The claims are dominated by Formula (I), Formula (II), and Formula (III) compound claims that define the spiro-fused quinazoline scaffold through extensive substituent selections and ring-forming W options. The claim set also includes an enumerated selection of specific spiro-fused quinazoline embodiments and a PDE7-mediated therapeutic use claim tied to administration of the claimed compounds.
Stated Advantages
PDE7 inhibition is presented as beneficial in neurocognitive/neurological settings.
PDE7 is presented as a cognition target.
Enhancement of neuroplasticity.
Neuroprotection.
Anti-inflammatory effects.
Therapeutic treatment of neurological, cognitive, immunological, and inflammatory conditions.
Augmentation of cognitive and motor training in rehabilitation contexts, including post-stroke rehabilitation and post-traumatic brain injury (TBI) rehabilitation.
Utility in metabolic studies and reaction kinetic studies.
Utility in detection and imaging techniques.
Utility in radioactive treatments.
Documented Applications
A method for treating, inhibiting, relieving, or ameliorating a disorder symptom in a subject with an aberrant or dysregulated PDE7-mediated signaling pathway by administering a compound of claim 1 or a pharmaceutically acceptable salt thereof.
Use in memory assessment contexts, including PDE7B knockdown effects on memory in mice and compound effects on memory in rats.
Use in stroke-related sensorimotor recovery contexts, including compound effects in a rat stroke model.
Therapeutic treatment of neurological and peripheral disorders using PDE7 inhibition.
Augmentation of cognitive and motor training during rehabilitation, including post-stroke rehabilitation and post-traumatic brain injury (TBI) rehabilitation.
Animal training protocols.
Metabolic studies.
Reaction kinetic studies.
Detection and imaging techniques.
Radioactive treatments.
Interested in licensing this patent?